Home / Expertise / Life Sciences & Healthcare
side view of scientist looking into microscope in bright research lab

Life Sciences & Healthcare

Austria

With over 150 international specialist lawyers across CMS and the support of the Life Sciences Asia-Pacific Network (LAN), we understand the scientific and commercial as well as the legal imperatives affecting your life sciences & healthcare business. We work with and have established long-term relationships with the top 100 life sciences & healthcare companies in the areas of pharmaceuticals, medical devices, biotechnology, agriculture and food, including the top 20 global pharmaceutical companies and nine out of the top ten global medical device companies.

Our experts, many of whom have worked in-house in your sector, have developed a shared capability in the areas of pharmaceuticals, biotechnology, medical devices and diagnostics. With active memberships in major industry associations we help shape the legal frameworks impacting the life sciences & healthcare sector.

We regularly advise our clients on their day-to-day operational needs such as support with advertisement and promotion of medicine, public sector procurement, pricing and reimbursement, patent enforcement, commercial and clinical trial agreements as well as regulatory advice and compliance. Equally, when you need life sciences & healthcare specialist advice for strategic agreements, planning a corporate transaction or embarking on litigation (whether product liability or otherwise), we have a team that is well versed in the industry issues to help you.

Read more Read less

Choose area

    Medical Law

    Legal questions are becoming increasingly relevant in the medical field, driven in part by the intended austerity and restructuring mandates of recent years. How do health care institutions comply with the multitude of legal requirements and yet still remain commercially viable? This is just one of the many challenges that we can help you meet.

    Read more

    Feed

    Show only
    01/03/2019
    BREXIT: What do phar­ma­ceut­ic­al and med­ic­al device com­pan­ies need to do?
    CMS in­forms phar­ma­ceut­ic­al and med­ic­al device com­pan­ies, what they need to do fa­cing Brexit. Read more here ✓
    20 April 2020
    CMS Ex­pert Guide to Ad­vert­ising of Medi­cines and Med­ic­al Devices
    Are you look­ing for in­form­a­tion on phar­ma­ceut­ic­al ad­vert­ising reg­u­la­tion and med­ic­al device ad­vert­ising? Learn more about it in this CMS Ex­pert Guide.
    02 July 2020
    EU agrees new class ac­tion re­gime for con­sumer dis­putes
    After a long gest­a­tion, on 30 June 2020 the Coun­cil of the EU pub­lished the text for the col­lect­ive re­dress dir­ect­ive (the “CR Dir­ect­ive”) (text avail­able here). This le­gis­la­tion is in­ten­ded to bet­ter...
    17/05/2018
    Dis­tri­bu­tion and mar­ket­ing of drugs in Aus­tria: over­view
    A Q&A guide to dis­tri­bu­tion and mar­ket­ing of drugs law in Aus­tria
    20 April 2020
    CMS Ex­pert Guide to a Leg­al Roadmap to Can­nabis
    Are you look­ing for in­form­a­tion on can­nabis law and le­gis­la­tion? This CMS Ex­pert Guide provides you with everything you need to know.
    26 May 2020
    European Com­mis­sion must ad­dress in­tel­lec­tu­al prop­erty and AI
    The Com­mit­tee on Leg­al Af­fairs (JURI) of the European Par­lia­ment has pub­lished three draft re­ports re­lat­ing to ar­ti­fi­cial in­tel­li­gence (AI). This note is about the draft re­port on in­tel­lec­tu­al prop­erty...
    15/01/2018
    Lifes­ci­ences Ex­pert Gab­ri­ela Staber Ap­poin­ted Part­ner at CMS
    22 May 2020
    For­eign in­vest­ments in Ger­man life sci­ence com­pan­ies be­come sub­ject to...
    In re­sponse to the COV­ID-19 pan­dem­ic, Ger­many has widened the scope of its in­vest­ment con­trol to in­clude nu­mer­ous life sci­ence com­pan­ies. The amend­ments to the For­eign Trade and Pay­ments Or­din­ance ("AWV")...
    01/01/2018
    For a healthy pro­spect
    Bro­chure Lifes­ci­ences
    04 May 2020
    EPO Board of ap­peal re­mits to ex­amin­ing di­vi­sion when pri­or art search...
    In Mod­el de­term­in­a­tion sys­tem/Ac­cen­ture Glob­al Ser­vices Lim­ited (Case T-1159/15), the board of ap­peal finds that need to per­form a pri­or art search con­sti­tutes a spe­cial reas­on to re­mit the ap­peal ap­plic­a­tion...
    01/01/2018
    Good medi­cine in­stead of bit­ter pills
    Bro­chure Med­ic­al Law
    30 April 2020
    USPTO finds an in­ven­tion cre­ated by an AI ma­chine is not pat­entable
    The US Pat­ent and Trade Mark Of­fice has found that DABUS is not a per­son and so can­not be con­sidered an in­vent­or of a pat­ent. DABUS is an ar­ti­fi­cial in­tel­li­gence (AI) ma­chine. The USPTO ac­cep­ted the in­dic­a­tion...